Home > Journals > Gazzetta Medica Italiana Archivio per le Scienze Mediche > Past Issues > Gazzetta Medica Italiana Archivio per le Scienze Mediche 2018 September;177(9):415-6 > Gazzetta Medica Italiana Archivio per le Scienze Mediche 2018 September;177(9):458-67

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

ORIGINAL ARTICLE   

Gazzetta Medica Italiana Archivio per le Scienze Mediche 2018 September;177(9):458-67

DOI: 10.23736/S0393-3660.17.03534-3

Copyright © 2017 EDIZIONI MINERVA MEDICA

language: English

Open-label study on the effect of AISURICIN™, containing Quercetin, Prunus Cerasus and Vitamin C in adults with asymptomatic hyperuricemia and grade 1 borderline hypertension

Vincenzo MONTEMURRO

Clinic of Cardiology, Presidio “Scillesi d’America”, Scilla, ASP Reggio Calabria, Reggio Calabria, Italy


PDF


BACKGROUND: Hyperuricemia has recently proved to be associated not only with gout, but also with cardiovascular diseases, such as arterial hypertension, ischemic stroke and acute or chronic heart failure, independently of the deposition of urate crystals. This study was designed to assess the effects of an innovative food supplement, AISURICIN™ on hyperuricemia and blood pressure in real world clinical practice. The inflammatory pattern (cytokines) was also assessed in a sub-set of patients.
METHODS: Eighty-four patients of both genders with asymptomatic hyperuricemia and concomitant grade 1 borderline systolic/diastolic hypertension were given AISURICIN™ containing Quercetin, Prunus Cerasus and Vitamin C for 4 weeks. Uric acid levels and systolic and diastolic blood pressure (SBP and DBP) were measured before and after treatment. Cytokine levels (IL-6 and TNF-alpha) were measured in 34 patients.
RESULTS: AISURICIN™ significantly reduced mean uric acid levels (from 6.9 mg/dL down to 5.5 mg/dL; P<0.02) and mean blood pressure (SBP from 143 mmHg down to 136 mmHg P<0.04 and DBP from 93 mmHg to 86 mmHg P<0.05). Both mean IL-6 and mean TNF-alpha were also significantly reduced (IL-6 from 6.38 pg/mL to 4.21 pg/mL P<0.03; TNF-alpha from 7.98 pg/mL to 3.8 pg/mL P<0.01). Tolerability was very good, with the exception of a few nonspecific gastric disturbances.
CONCLUSIONS: In patients with asymptomatic hyperuricemia, AISURICIN™, thanks to the synergism of action among its ingredients and its very good tolerability, has proved to be a valid alternative to the standard of care, also in view of its protective effects against cardiovascular risk.


KEY WORDS: Quercetin - Prunus - Vitamin C - Hyperuricemia - Hypertension

top of page